Umecrine Cognition AB

Umecrine Cognition AB is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, and a subsidiary of Umecrine AB.

The company focuses on developing innovative small-molecule therapeutics for neurological disorders linked to neuroinflammation and GABA-A receptor overactivation in the central nervous system. Umecrine Cognition specializes in first-in-class drug candidates aimed at addressing cognitive impairment, central fatigue, and alertness deficits associated with conditions like chronic liver disease. Its lead candidate, golexanolone, is designed to normalize brain signaling and alleviate symptoms in conditions such as Primary Biliary Cholangitis (PBC) and Hepatic Encephalopathy (HE). The company is actively conducting clinical studies and has received FDA Orphan Drug Designation for golexanolone in PBC. Umecrine Cognition is committed to advancing its pipeline and exploring partnerships for commercialization, targeting significant patient populations with unmet medical needs.